Simon Latour

Simon Latour

Auto-generated profile, based on publicly available information

Simon Latour

Department of Chemical Engineering and Applied Chemistry, University of Toronto

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2017 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
AGAgathe Grémare
Agathe Grémare
VGVera Guduric
Vera Guduric
RBReine Bareille
Reine Bareille
VHValérie Heroguez
Valérie Heroguez
SLSimon Latour
Simon Latour
DNDamien Le Nihouannen
Damien Le Nihouannen

9 December 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
CLClaire Lamaison
Claire Lamaison
SLSimon Latour
Simon Latour
NHNelson Hélaine
Nelson Hélaine
VMValérie Le Morvan
Valérie Le Morvan
JSJulien Saint-Vanne
Julien Saint-Vanne
LBLaurence Bresson-bepoldin
Laurence Bresson-bepoldin
Non-Hodgkin B-cell lymphomas (B-NHL) mainly develop within lymph nodes as aggregates of tumor cells densely packed with their surrounding microenvironment, creating a tumor niche specific to each lymphoma subtypes. In vitro preclinical models mimicking biomechanical forces, cellular microenvironment, and 3D organization of B-cell lymphomas remain scarce, while all these parameters are key determinants of lymphomagenesis and drug resistance. Using a microfluidic method based on cell encapsulation inside permeable, elastic, and hollow alginate microspheres, we developed a new tunable 3D model incorporating lymphoma B cells, extracellular matrix (ECM), and/or tonsil stromal cells (TSC). Under 3D confinement, lymphoma B cells were able to form cohesive spheroids resulting from overexpression of ECM components. Moreover, lymphoma B cells and TSC dynamically formed self-organized 3D spheroids favoring tumor cell growth. 3D culture induced resistance to the classical chemotherapeutic agent doxorubicin, but not to the BCL2 inhibitor ABT-199, identifying this approach as a relevant in vitro model to assess the activity of therapeutic agents in B-NHL. RNA-sequence analysis highlighted the synergy of 3D, ECM, and TSC in upregulating similar pathways in malignant B cells in vitro than those overexpressed in primary lymphoma B cells in situ. Finally, our 3D model including ECM and TSC allowed long-term in vitro survival of primary follicular lymphoma B cells. In conclusion, we propose a new high-throughput 3D model mimicking lymphoma tumor niche and making it possible to study the dynamic relationship between lymphoma B cells and their microenvironment and to screen new anti-cancer drugs.

1 September 2015 in The Journal of Immunology
Verified
Journal Article
Closed access
VVVACHER Vacher
VACHER Vacher
AVAnne-Marie Vacher
Anne-Marie Vacher
RPRaphael Pineau
Raphael Pineau
SLSimon Latour
Simon Latour
ISIsabelle Soubeyran
Isabelle Soubeyran
LBLaurence Bresson-bepoldin
Laurence Bresson-bepoldin
The anti-CD20 mAb, rituximab, is routinely used to treat B cell malignancies. However, a majority of patients relapse. An improvement in the complete response was obtained by combining rituximab with chemotherapy, at the cost of increased toxicity. We reported that rituximab induced the colocalization of both the Orai1 Ca2+ release-activated Ca2+ channel (CRAC) and the endoplasmic reticulum Ca2+ sensor stromal interaction molecule 1 with CD20 and CD95 into a cluster, eliciting a polarized store-operated Ca2+ entry (SOCE). We observed that blocking this Ca2+ entry with downregulation of Orai1, pharmacological inhibitors, or reducing calcemia with hypocalcemic drugs sensitized human B lymphoma cell lines and primary human lymphoma cells to rituximab-induced apoptosis in vitro, and improved the antitumoral effect of rituximab in xenografted mice. This revealed that Ca2+ entry exerted a negative feedback loop on rituximab-induced apoptosis, suggesting that associating CRAC channel inhibitors or hypocalcemic agents with rituximab may improve the treatment of patients with B cell malignancies. The calcium-dependent proteins involved in this process appear to vary according to the B lymphoma cell type, suggesting that CRAC-channel targeting is likely to be more efficient than calcium-dependent protein targeting.

27 October 2022 in Biomaterials
Verified
Journal Article
Closed access
NLNancy T. Li
Nancy T. Li
NWNila C. Wu
Nila C. Wu
RCRuonan Cao
Ruonan Cao
JCJose L. Cadavid
Jose L. Cadavid
SLSimon Latour
Simon Latour
AMAlison P. P McGuigan
Alison P. P McGuigan

10 May 2023 in Advanced Healthcare Materials
Verified
Journal Article
Open access
RCRuonan Cao
Ruonan Cao
NLNancy T. Li
Nancy T. Li
SLSimon Latour
Simon Latour
JCJose L. Cadavid
Jose L. Cadavid
CTCassidy M. Tan
Cassidy M. Tan
AMAlison P. P McGuigan
Alison P. P McGuigan
Patient‐derived organoids have emerged as a useful tool to model tumour heterogeneity. Scaling these complex culture models while enabling stratified analysis of different cellular sub‐populations, however, remains a challenge. One strategy to enable higher throughput organoid cultures is the scaffold‐supported platform for organoid‐based tissues (SPOT). SPOT allows the generation of flat, thin, and dimensionally‐defined microtissues in both 96‐ and 384‐well plate footprints that are compatible with longitudinal image‐based readouts. SPOT is currently manufactured manually, however, limiting scalability. In this study, an automation approach to engineer tumour‐mimetic 3D microtissues in SPOT using a liquid handler is optimized and comparable within‐ and between‐sample variation to standard manual manufacturing is shown. Further, a liquid handler‐supported cell extraction protocol to support single‐cell‐based end‐point analysis using high‐throughput flow cytometry and multiplexed cytometry by time of flight is developed. As a proof‐of‐value demonstration, 3D complex tissues containing different proportions of tumour and stromal cells are generated to probe the reciprocal impact of co‐culture. It is also demonstrated that primary patient‐derived organoids can be incorporated into the pipeline to capture patient‐level tumour heterogeneity. It is envisioned that this automated 96/384‐SPOT workflow will provide opportunities for future applications in high‐throughput screening for novel personalized therapeutic targets.

16 February 2022 in Biomaterials
Verified
Journal Article
Closed access
NWNila C. Wu
Nila C. Wu
JCJose L. Cadavid
Jose L. Cadavid
XTXinzhu Tan
Xinzhu Tan
SLSimon Latour
Simon Latour
SSStefano Scaini
Stefano Scaini
AMAlison P. P McGuigan
Alison P. P McGuigan